The collaboration between Classiq, a leader in quantum computing software, and Quantum Intelligence Corp. (QIC) from Korea, represents a significant leap forward in the application of quantum computing within the life sciences and healthcare sectors. This partnership, centered around Classiq's Quantum Computing For Life Sciences & Healthcare Center, is set to explore the vast potential of quantum computing in transforming the drug development process. By integrating Classiq's advanced quantum computing platform with QIC's innovative drug development platform, the alliance aims to streamline the discovery of new drug candidates and improve the accuracy of predicting adverse effects and drug interactions.
QIC's CEO, Hwanho Choi, MD., PhD, highlighted the unique position of Quantum Intelligence as a platform company that diverges from traditional biopharmaceutical approaches by harnessing the power of quantum and AI technologies. The collaboration is expected to enable early identification of potential side effects, thereby mitigating risks throughout the drug development and clinical trial phases. QIC's QUEST-ADMET platform, a pioneering tool in the field, utilizes quantum computing and AI to predict compound properties through electronic charge distribution algorithms, offering a novel approach to assessing the efficacy and safety of drug candidates.
Nir Minerbi, CEO of Classiq, underscored the transformative potential of this agreement, pointing towards a future where drug development is significantly accelerated through quantum computing. Classiq's platform, known for its high-level abstraction capabilities, simplifies the creation of complex quantum software and applications. Its comprehensive features, including a GitHub repository and compatibility with quantum computing hardware, are poised to play a pivotal role in advancing pharmacological research. This partnership not only exemplifies the growing intersection between quantum computing and healthcare but also sets a precedent for future collaborations aimed at tackling some of the most pressing challenges in drug development.
